TAK peer analysis
Takeda (TAK) against its competitors: price, today's move, 1-year return and market value side by side.
TAK and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AMGN Amgen | $466.80 | 0.17% | 59.86% | $251.94B |
| AZN AstraZeneca | $186.61 | -0.02% | 13.32% | $289.48B |
| BMY Bristol-Myers Squibb | $63.29 | 1.30% | 38.73% | $127.71B |
| GRFS Grifols | $8.10 | 0.75% | -11.57% | $5.51B |
| LLY Eli Lilly | $1,413.00 | -0.32% | 67.32% | $1.26T |
| MRK Merck | $148.44 | -0.72% | 72.04% | $368.89B |
| PFE Pfizer | $31.04 | 1.70% | 27.79% | $173.95B |
| SNY Sanofi | $45.54 | 2.71% | -10.60% | $106.24B |
| TAK Takeda | $20.88 | -0.14% | 57.82% | $66.81B |
- TAK's peers: AMGN (Amgen), AZN (AstraZeneca), BMY (Bristol-Myers Squibb), GRFS (Grifols), LLY (Eli Lilly), MRK (Merck), PFE (Pfizer), SNY (Sanofi).
Updated 2026-11-03 00:13 UTC